Frontiers in Neurology (Dec 2017)

Tranylcypromine Causes Neurotoxicity and Represses BHC110/LSD1 in Human-Induced Pluripotent Stem Cell-Derived Cerebral Organoids Model

  • Jing Huang,
  • Jing Huang,
  • Fangkun Liu,
  • Hui Tang,
  • Hui Tang,
  • Haishan Wu,
  • Haishan Wu,
  • Lehua Li,
  • Lehua Li,
  • Renrong Wu,
  • Renrong Wu,
  • Jingping Zhao,
  • Jingping Zhao,
  • Ying Wu,
  • Zhixiong Liu,
  • Jindong Chen,
  • Jindong Chen

DOI
https://doi.org/10.3389/fneur.2017.00626
Journal volume & issue
Vol. 8

Abstract

Read online

Recent breakthroughs in human pluripotent stem cell-derived cerebral organoids provide a valuable platform for investigating the human brain after different drugs treatments and for understanding the complex genetic background to human pathology. Here, we identified tranylcypromine, which is used to treat refractory depression, caused human-induced pluripotent stem cell-derived brain organoids neurotoxicity, leading to decreased proliferation activity and apoptosis induction. Moreover, tranylcypromine treatment affects neurons and astrocytes, which impairs cell density and arrangement. Finally, staining of histone demethylation-related genes revealed that tranylcypromine suppresses the transcriptional activity of BHC110/LSD1-targeted genes and increases the expression of histone di-methylated K4. These results show that human brain organoids can be applied as an in vitro model for CNS drug screening to evaluate structural, cellular, and molecular changes in the normal brains or brains of patients with neuropsychiatric disorders after drug treatments.

Keywords